c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty

Markus A. Seeliger(Howard Hughes Medical Institute), John Kuriyan(Vanderbilt University), Filipp Frank, Max Henderson(Howard Hughes Medical Institute), Bhushan Nagar(McGill University), Xiaoxian Cao(QB3)

Structure

March 1, 2007

10.1016/j.str.2007.01.015

Cited by 226

Related Papers

Crystallographic <i>R</i> Factor Refinement by Molecular Dynamics

|Science|1987|2k

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

|Science|2000|1.8k

The Conformational Plasticity of Protein Kinases

|Cell|2002|1.8k

An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor

|Cell|2006|1.6k

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

|Cancer Cell|2002|1.6k